The Israeli Ministry of Health said it will investigate a small number of myocarditis cases in people who have been vaccinated with Pfizera against COVID-19. It is not clear if this is related to vaccination.
/Amir Levy /Getty Images
The head of the government epidemic team, Prof. Wehman Asses. He said that the initial analysis identified 62 cases of myocarditis in more than five million people who were vaccinated, especially after the second dose, and in men under the age of thirty. However, he emphasized, it is unclear if this number is higher than normal and whether the recorded cases are related to vaccination. He added that the Ministry of Health is investigating the matter.
Asses also noted that this disease, which often resolves without complications, can be caused by a number of viral infections and other factors.
According to Pfizer, an unusual elevation of this condition has not been observed in the vaccine.
The company said: “We have not seen an increase in myocarditis incidence compared to the general population. (…) There is currently no evidence to claim that myocarditis is a risk associated with the use of the Pfizer / BioNTech vaccine.” As part of an agreement with the Israeli government, Pfizer has access to a medical database of vaccines.
The group’s vaccine has so far received nearly 60 percent. With nearly nine million residents of Israel. Since the start of the vaccination campaign, the number of new infections and deaths has decreased sharply, from 10,000 to 10,000. daily in January to the current level of about 80 infections in the past two days.
According to Reuters, Prof. Nadaw Dawidowicz of Ben-Gurion University, even if there was a link between the disease and the use of the vaccine, the risk would be small and temporary, much less than COVID-19.